South Africa’s R15.5bn HIV Drug Tender Faces Scrutiny Over ‘Local Manufacturing’ Claims
South Africa’s R15.5 billion antiretroviral (ARV) procurement programme, which supplies treatment to roughly eight million people, is under parliamentary scrutiny after officials conceded they have not verified whether the majority of medicines are genuinely produced locally. The Department of Health has long maintained that at least 70% of ARVs under the national tender are sourced…
